Loading
Paper cited by one bottleneck page and 21 idea pages, indexed on Europe PMC as PubMed record 28290490 and published in Nature Reviews Clinical Oncology; the citing pages link this DOI, which is how the record was matched.
Globally, annual spending on anticancer drugs is around US$100 billion, and is predicted to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than $100,000 per year of treatment. When adjusted for per capita spending power, however, drugs are most unaffordable in economically developing nations, such as India and China. Not only are launch prices high and rising, but individual drug prices are often escalated during exclusivity periods. High drug prices harm patients - often directly through increased out-of-pocket expenses, which reduce levels of patient compliance and lead to unfavourable outcomes - and harms society - by imposing cumulative price burdens that are unsustainable. Moreover, high drug prices are not readily explained by rational factors, including the extent of benefit patients are likely to derive, the novelty of the agents, or spending on research and development. Herein, we summarize the available empirical evidence on the costs of anticancer drugs, probe the origins and implications of these high costs, and discuss proposed solutions.
Indexed on Europe PMC as PubMed record 28290490 (DOI 10.1038/nrclinonc.2017.31). Matched by DOI alone: one bottleneck page and 21 idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One bottleneck page and 21 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares A joint price negotiation bloc for middle-income countries, modelled on Beneluxa, Grant extra exclusivity only in exchange for binding low prices in poorer countries, Biosimilar-first defaults and payment parity in every cancer day unit, Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales.
Shares Pay for one-time curative therapies as an annuity that stops at relapse, Prices and value.
Shares Public payers cover academic CAR-T at cost as a benchmark for commercial prices, Prices and value.